T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation: Results, Barriers, and Future Directions

Robert J. Soiffer

doi:10.1017/9781316335727.030

Chapter 29 - T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation: Results, Barriers, and Future Directions

from Section 9 - Selection of Conditioning Regimen and Challenges with Different Types of T-Cell Depletion Methods

Published online by Cambridge University Press: 24 May 2017

Edited by

Reinhold Munker and

Edited in association with

Syed Ali Abutalib

Show author details

Hillard M. Lazarus: Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale: Affiliation:
Imperial College London
Armand Keating: Affiliation:
University of Toronto
Andrea Bacigalupo: Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker: Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson: Affiliation:
University of Queensland
Syed Ali Abutalib: Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago

Book contents

Get access

Type: Chapter
Information: Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
, pp. 271 - 282

DOI: https://doi.org/10.1017/9781316335727.030 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Socie, G, Stone, JV, Wingard, JR, et al: Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341:14–21, 1999CrossRef Google Scholar PubMed

Patterson, J, Prentice, HG, Brenner, MK, et al: Graft rejection following HLA-matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 63:221–30, 1986Google Scholar

Zutter, MM, Martin, PJ, Sale, GE, et al: Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520–9, 1988Google Scholar

Marmont, AM, Horowitz, MM, Gale, RP, et al: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120–30, 1991CrossRef Google Scholar PubMed

Goldman, JM, Gale, RP, Horowitz, MM, et al: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806–14, 1988Google Scholar

Wagner, JE, Thompson, JS, Carter, SL, et al: Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366:733–41, 2005CrossRef Google Scholar

Marek, A, Stern, M, Chalandon, Y, et al: The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant 49:55–61, 2014CrossRef Google Scholar PubMed

Kernan, NA, Collins, NH, Juliano, L, et al: Clonable T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 68:770–773, 1986CrossRef Google Scholar

Wagner, JE, Donnenberg, AD, Noga, SJ, et al: Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood 72:1168–76, 1988Google Scholar

Urbano-Ispizua, A, Rozman, C, Pimentel, P, et al: The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 97:383–7, 2001Google Scholar

Kanate, AS, Craig, M, Cumpston, A, et al: Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 4:149–56, 2011Google Scholar

Champlin, RE, Passweg, JR, Zhang, MJ, et al: T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95:3996–4003, 2000Google Scholar

Soiffer, RJ, Gonin, R, Murray, C, et al: Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood 82:2216–23, 1993CrossRef Google Scholar PubMed

Nimer, SD, Giorgi, J, Gajewski, JL, et al: Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 57:82–7, 1994CrossRef Google Scholar PubMed

Ho, VT, Kim, HT, Li, S, et al: Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 34:987–94, 2004Google Scholar

Alyea, EP, Soiffer, RJ, Canning, C, et al: Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671–80, 1998CrossRef Google Scholar PubMed

Meyer, RG, Britten, CM, Wehler, D, et al: Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 109:374–82, 2007Google Scholar

Antin, JH, Bierer, BE, Smith, BR, et al: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139–49, 1991CrossRef Google Scholar PubMed

Soiffer, RJ, Murray, C, Mauch, P, et al: Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 10:1191–200, 1992Google Scholar

Filipovich, AH, Vallera, D, McGlave, P, et al: T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation 50:410–5, 1990CrossRef Google Scholar PubMed

Hale, G, Jacobs, P, Wood, L, et al: CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 26:69–76, 2000CrossRef Google Scholar PubMed

Young, JW, Papadopoulos, EB, Cunningham, I, et al: T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 79:3380–7, 1992Google Scholar

Kernan, NA, Bartsch, G, Ash, RC, et al: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593–602, 1993Google Scholar

Bensinger, WI, Buckner, CD, Shannon-Dorcy, K, et al: Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 88:4132–8, 1996CrossRef Google Scholar PubMed

Urbano-Ispizua, A, Solano, C, Brunet, S, et al: Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Bone Marrow Transplant 22:519–25, 1998Google Scholar

O’Donnell, PV, Myers, B, Edwards, J, et al: CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts. Cytotherapy 3:483–8, 2001Google Scholar

Jakubowski, AA, Small, TN, Kernan, NA, et al: T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 17:1335–42, 2011Google Scholar

Devine, SM, Carter, S, Soiffer, RJ, et al: Low-risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 17:1343–51, 2011Google Scholar

Keever-Taylor, CA, Devine, SM, Soiffer, RJ, et al: Characteristics of CliniMACS(R) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant 18:690–7, 2012CrossRef Google Scholar

Pasquini, MC, Devine, S, Mendizabal, A, et al: Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 30:3194–201, 2012Google Scholar

Bayraktar, UD, de Lima, M, Saliba, RM, et al: Ex vivo T cell depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant,19:898–903, 2013CrossRef Google Scholar PubMed

Soiffer, RJ, Mauch, P, Fairclough, D, et al: CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant 3:11–7, 1997Google Scholar PubMed

Mehta, J, Singhal, S, Gee, AP, et al: Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 33:389–96, 2004CrossRef Google Scholar PubMed

Aversa, F, Tabilio, A, Velardi, A, et al: Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339:1186–93, 1998CrossRef Google Scholar PubMed

Marks, DI, Khattry, N, Cummins, M, et al: Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol 134:196–201, 2006Google Scholar

Ciceri, F, Labopin, M, Aversa, F, et al: A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 112:3574–81, 2008Google Scholar

Ruggeri, L, Capanni, M, Casucci, M, et al: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333–9, 1999Google Scholar

Hsu, KC, Keever-Taylor, CA, Wilton, A, et al: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105:4878–84, 2005Google Scholar

Geyer, MB, Ricci, AM, Jacobson, JS, et al: T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. Br J Haematol 157:205–19, 2012Google Scholar

Di Ianni, M, Falzetti, F, Carotti, A, et al: Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117:3921–8, 2011Google Scholar

Bertaina, A, Merli, P, Rutella, S, et al: HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood 124:822–6, 2014Google Scholar

Bashey, A, Solomon, SR: T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant 49:999–1008, 2014Google Scholar

Luznik, L, O’Donnell, PV, Symons, HJ, et al: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641–50, 2008Google Scholar

Ayuk, F, Maywald, N, Hannemann, S, et al: Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. Anticancer Res 29:1355–60, 2009Google Scholar

Russell, JA, Turner, AR, Larratt, L, et al: Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 13:299–306, 2007Google Scholar

Bredeson, CN, Zhang, MJ, Agovi, MA, et al: Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 14:993–1003, 2008Google Scholar

Mohty, M, Labopin, M, Balere, ML, et al: Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 24:1867–74, 2010CrossRef Google Scholar PubMed

Malladi, RK, Peniket, AJ, Littlewood, TJ, et al: Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant 43:709–15, 2009CrossRef Google Scholar PubMed

Veys, P, Wynn, RF, Ahn, KW, et al: Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 119:6155–61, 2012CrossRef Google Scholar PubMed

Bacigalupo, A, Lamparelli, T, Bruzzi, P, et al: Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98:2942–7, 2001CrossRef Google Scholar PubMed

Bacigalupo, A, Lamparelli, T, Barisione, G, et al: Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12:560–5, 2006Google Scholar

Finke, J, Bethge, WA, Schmoor, C, et al: Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10:855–64, 2009CrossRef Google Scholar PubMed

Socie, G, Schmoor, C, Bethge, WA, et al: Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 117:6375–82, 2011CrossRef Google Scholar PubMed

Westphal, S, Brinkmann, H, Kalupa, M, et al: Anti-tumor effects of anti-T-cell globulin. Exp Hematol 42:875–82, 2014Google Scholar

Walker, I, Schultz, KR, Toze, CL, et al: Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. Blood 124:38, 2014Google Scholar

Yu, ZP, Ding, JH, Wu, F, et al: Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. Biol Blood Marrow Transplant 18:593–9, 2012Google Scholar

Perez-Simon, JA, Kottaridis, PD, Martino, R, et al: Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100:3121–7, 2002Google Scholar PubMed

Chakrabarti, S, Mackinnon, S, Chopra, R, et al: High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99:4357–63, 2002Google Scholar

Mohty, M, Jacot, W, Faucher, C, et al: Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17:2168–77, 2003Google Scholar

Peggs, KS, Kayani, I, Edwards, N, et al: Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol 29:971–8, 2011Google Scholar

Thomson, KJ, Morris, EC, Milligan, D, et al: T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 28:3695–700, 2010Google Scholar

Koreth, J, Kim, HT, Nikiforow, S, et al: Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant 20:1516–21, 2014CrossRef Google Scholar PubMed

Baron, F, Schaaf-Lafontaine, N, Humblet-Baron, S, et al: T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation 76:1705–13, 2003Google Scholar

Soiffer, RJ, Lerademacher, J, Ho, V, et al: Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117:6963–70, 2011Google Scholar

Baron, F, Labopin, M, Niederwieser, D, et al: Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 26:2462–8, 2012Google Scholar

Baron, F, Labopin, M, Blaise, D, et al: Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49:389–96, 2014Google Scholar

Wolschke, C, Zabelina, T, Ayuk, F, et al: Effective prevention of GvHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation. Bone Marrow Transplant 49:126–30, 2014CrossRef Google Scholar PubMed

Devillier, R, Crocchiolo, R, Castagna, L, et al: The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 47:639–45, 2012Google Scholar

Mohty, M, Bay, JO, Faucher, C, et al: Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102:470–6, 2003CrossRef Google Scholar PubMed

Ayuk, F, Diyachenko, G, Zabelina, T, et al: Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14:913–9, 2008Google Scholar

Wang, Y, Fu, HX, Liu, DH, et al: Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant 49:426–33, 2014Google Scholar

Remberger, M, Sundberg, B: Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 15:996–9, 2009Google Scholar

Podgorny, PJ, Ugarte-Torres, A, Liu, Y, et al: High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 16:915–26, 2010Google Scholar

Remberger, M, Persson, M, Mattsson, J, et al: Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. Transpl Immunol 27:59–62, 2012Google Scholar

Hoegh-Petersen, M, Amin, MA, Liu, Y, et al: Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse. Bone Marrow Transplant 48:105–14, 2013Google Scholar

Jol-van der Zijde, CM, Bredius, RG, Jansen-Hoogendijk, AM, et al: Antibodies to anti-thymocyte globulin in aplastic anemia patients have a negative impact on hematopoietic SCT. Bone Marrow Transplant 47:1256–8, 2012Google Scholar

Ho, VT, Weller, E, Lee, SJ, et al: Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:223–9, 2001CrossRef Google Scholar PubMed

Huisman, C, van der Straaten, HM, Canninga-van Dijk, MR, et al: Pulmonary complications after T-cell-depleted allogeneic stem cell transplantation: low incidence and strong association with acute graft-versus-host disease. Bone Marrow Transplant 38:561–6, 2006Google Scholar

Moscardo, F, Urbano-Ispizua, A, Sanz, GF, et al: Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 31:545–50, 2003Google Scholar

Voogt, PJ, Fibbe, WE, Marijt, WA, et al: Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet 335:131–4, 1990Google Scholar

Fleischhauer, K, Kernan, NA, O’Reilly, RJ, et al: Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 323:1818–22, 1990Google Scholar

Jakubowski, AA, Small, TN, Young, JW, et al: T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 110:4552–9, 2007Google Scholar

Burnett, AK, Hann, IM, Robertson, AG, et al: Prevention of graft-versus-host disease by ex vivo T cell depletion: reduction in graft failure with augmented total body irradiation. Leukemia 2:300–3, 1988Google Scholar

Roux, E, Helg, C, Dumont-Girard, F, et al: Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87:3984–92, 1996Google Scholar

Wu, CJ, Chillemi, A, Alyea, EP, et al: Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood 95:352–9, 2000CrossRef Google Scholar PubMed

Hochberg, EP, Chillemi, AC, Wu, CJ, et al: Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood 98:1116–21, 2001CrossRef Google Scholar PubMed

Small, TN, Papadopoulos, EB, Boulad, F, et al: Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 93:467–80, 1999Google Scholar

Bosch, M, Dhadda, M, Hoegh-Petersen, M, et al: Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 14:1258–75, 2012CrossRef Google Scholar PubMed

Avivi, I, Chakrabarti, S, Milligan, DW, et al: Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 10:186–94, 2004CrossRef Google Scholar PubMed

van Burik, JA, Carter, SL, Freifeld, AG, et al: Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 13:1487–98, 2007Google Scholar

Brunstein, CG, Weisdorf, DJ, DeFor, T, et al: Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108:2874–80, 2006Google Scholar

Lindemans, CA, Chiesa, R, Amrolia, PJ, et al: Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 123:126–32, 2014Google Scholar

Kuehnle, I, Huls, MH, Liu, Z, et al: CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95:1502–5, 2000Google Scholar

Stevens, SJ, Verschuuren, EA, Pronk, I, et al: Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 97:1165–71, 2001Google Scholar

Papadopoulos, EB, Ladanyi, M, Emanuel, D, et al: Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185–91, 1994Google Scholar

Doubrovina, E, Oflaz-Sozmen, B, Prockop, SE, et al: Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119:2644–56, 2012Google Scholar

Gerdemann, U, Keirnan, JM, Katari, UL, et al: Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20:1622–32, 2012Google Scholar

Leen, AM, Myers, GD, Sili, U, et al: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:1160–6, 2006Google Scholar

Perales, MA, Goldberg, JD, Yuan, J, et al: Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 120:4882–91, 2012Google Scholar

Goldberg, GL, Alpdogan, O, Muriglan, SJ, et al: Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation. J Immunol 178:7473–84, 2007Google Scholar

Hessner, MJ, Endean, DJ, Casper, JT, et al: Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86:3987–96, 1995Google Scholar

Devergie, A, Apperley, JF, Labopin, M, et al: European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:11–9, 1997Google Scholar

Sullivan, KM, Weiden, PL, Storb, R, et al: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–8, 1989Google Scholar

Kolb, HJ, Mittermuller, J, Clemm, C, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–5, 1990Google Scholar

Collins, RH Jr., Shpilberg, O, Drobyski, WR, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433–44, 1997Google Scholar

Soiffer, RJ, Fairclough, D, Robertson, M, et al: CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 89:3039–47, 1997Google Scholar

Papadopoulos, EB, Carabasi, MH, Castro-Malaspina, H, et al: T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 91:1083–90, 1998Google Scholar

Remberger, M, Ringden, O, Aschan, J, et al: Long-term follow-up of a randomized trial comparing T-cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplant Proc 26:1829–30, 1994Google Scholar

Montero, A, Savani, BN, Shenoy, A, et al: T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 12:1318–25, 2006Google Scholar

Soiffer, RJ, Alyea, EP, Hochberg, E, et al: Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 8:625–32, 2002Google Scholar

Sehn, LH, Alyea, EP, Weller, E, et al: Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol 17:561–8, 1999Google Scholar

Chalandon, Y, Roosnek, E, Mermillod, B, et al: Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant 12:102–10, 2006Google Scholar

Peggs, KS, Sureda, A, Qian, W, et al: Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 139:70–80, 2007Google Scholar

Book contents

Chapter 29 - T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation: Results, Barriers, and Future Directions

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive